General Electric Company GE held a GE Healthcare investor day event this week. One analyst in attendance said Tuesday that Healthcare should be a stable source of free cash flow for GE as it executes its turnaround strategy, but the GE bull case still hinges on Power.
The Analyst
Bank of America analyst Andrew Obin reiterated his Neutral rating and $12 price target for GE stock.
The Thesis
Obin listed three major takeaways from the event for investors:
- Not including Biopharma, GE Healthcare should generate between $1.6 billion and $1.8 billion in free cash flow in 2020.
- GE’s digital offerings have grown large enough to potentially help expand Healthcare margins.
- There were no major surprises in GE’s Healthcare guidance of mid single-digit revenue growth and between 0.25% and 0.75% of margin expansion per year.
Including Biopharma, Obin projects $2.9 billion in 2020 free cash flow from GE Healthcare, down from $3 billion in 2018. He said Healthcare should be able to grow free cash flow in the high single digits starting in 2021.
“On balance, GE’s Power segment has more opportunity to drive either the Bull or Bear case,” Obin wrote in a note.
GE’s digital revenue is growing in the high single digits at margins of greater than 50%. Obin said the key risk to this growth is the potential for new competitor willing to sacrifice profits to gain market share.
Benzinga’s Take
The worst may finally be over for GE investors after years of market declines. However, GE will need to demonstrate it can generate sustainable cash flow and earnings growth to make the stock appealing to value investors.
GE's stock traded around $11 per share at time of publication.
Do you agree with this take? Email feedback@benzinga.com with your thoughts.
Related Links:
13 Stocks With The Highest Average Daily Trading Volume
Q3 13F Roundup: How Buffett, Einhorn, Ackman And Others Adjusted Their Portfolios
Photo credit: Momoneymoproblemz, via Wikimedia Commons
Edge Rankings
Price Trend
© 2025 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
---|
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.